PortfoliosLab logo
Phoenix Biotech Acquisition Corp. (PBAXU)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US71902K2042

CUSIP

71902K204

IPO Date

Oct 6, 2021

Highlights

Short Ratio

1.62

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Phoenix Biotech Acquisition Corp.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


PBAXU

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of PBAXU, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20242.61%-5.64%-3.17%
20230.00%0.00%0.00%0.00%4.27%1.49%-1.01%-0.19%-1.02%0.00%2.62%-2.19%3.88%
2022-0.50%0.30%-0.10%0.20%-0.30%0.18%0.22%-0.30%0.30%0.59%0.89%0.68%2.18%
20210.30%0.10%-0.30%0.10%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Phoenix Biotech Acquisition Corp. (PBAXU) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Phoenix Biotech Acquisition Corp.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Phoenix Biotech Acquisition Corp. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Phoenix Biotech Acquisition Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Phoenix Biotech Acquisition Corp. was 14.88%, occurring on Dec 22, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-14.88%Apr 25, 2023169Dec 22, 2023
-6.8%Jan 11, 2022258Jan 20, 202313Feb 8, 2023271
-4.49%Mar 24, 20232Mar 27, 202319Apr 24, 202321
-2.83%Feb 9, 20231Feb 9, 202329Mar 23, 202330
-1.86%Dec 3, 202117Dec 28, 20219Jan 10, 202226
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Phoenix Biotech Acquisition Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Phoenix Biotech Acquisition Corp., comparing actual results with analytics estimates.


-0.00-0.00-0.00-0.000.00
-0.00
0
Actual
Estimate

Valuation

The Valuation section provides an overview of how Phoenix Biotech Acquisition Corp. is priced in the market compared to other companies in the Shell Companies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for PBAXU relative to other companies in the Shell Companies industry. Currently, PBAXU has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for PBAXU in comparison with other companies in the Shell Companies industry. Currently, PBAXU has a P/B value of 0.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items